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Jane M Rayner, Jinxia Zhang, Gavin JD Smith, Wai-Lan 
Wu, Siu-Ying Lau, Pengxi Zhao, Malik JS Peiris, Yi Guan, 
Honglin Chen
State Key Laboratory for Emerging Infectious Diseases, Department of 
Microbiology, The University of Hong Kong, Hong Kong SAR, China
Resistance to the neuraminidase inhibitor, oseltamivir, was 
found in H5N1 virus isolated from infected patients in Vietnam 
but no recent avian H5N1 isolates have been reported to 
possess known neuraminidase inhibitor resistance mutations. It 
is still not clear whether the NA1 gene neuraminidase mutation, 
His274Tyr, detected in H5N1 infected human cases originated 
during disease treatment or came from the avian virus source. 
A 2002 HK chicken H5N1 isolate was found to contain the 
His274Tyr mutation on NA1 and resistance to oseltamivir was 
confirmed using a cell-based assay. To investigate if His274Tyr 
might naturally occur at low levels mixed with wild type in H5N1 
poultry infections we examined isolates from different hosts 
and geographical locations using a differential RT-PCR assay. 
The His274Ty quasi species was more frequently recognized in 
isolates from infected chickens than in isolates from ducks and 
geese, but no geographical difference was observed. Close 
surveillance of mutants in the virus population, combined with 
pursuit of alternative therapies, is essential to H5N1 pandemic 
containment strategies. 
Introduction
Outbreaks caused by avian influenza H5N1 virus have been 
reported in poultry in nine southeast Asian countries since 2003 
[1,2,3]. Increasing evidence shows H5N1 virus is endemic in 
poultry in this region; it may not be eradicable from avian hosts 
by regular control measures. The outbreak in migratory birds at 
Qinghai Lake in 2005 led to further expansion of the geographical 
distribution of H5N1 virus from Asia to Europe, the Middle-east 
and Africa [4,5]. Meanwhile, over 300 human infections by 
H5N1 virus have occurred in affected countries since 2003 [6]. 
There is concern that the H5N1 virus, or a derivative of it, may 
stand to be the next pandemic influenza virus [7]. It may still be 
some time before an effective vaccine, in adequate quantities, is 
available. This leaves protection in the face of a pandemic largely 
at the therapeutic level through antiviral treatment, placing 
emphasis on stockpiling antiviral drugs, particularly those for 
which resistance is not regularly detected [8]. Oseltamivir, a 
neuraminidase inhibitor, blocks exit of maturing virus particles 
from infected cells. In vivo and in vitro studies on H5N1 isolates 
from Vietnam and index strains from Hong Kong (1997 and 
2003) have shown that oseltamivir effectively inhibits virus 
replication [3, 9-11]. However, resistance to oseltamivir has been 
observed, albeit rarely, during treatment of H3N2 and H5N1 
influenza virus infections [12, 13-14]. This study examines H5N1 
sequence data to investigate the occurrence and distribution 
of oseltamivir resistant mutants isolated in Asia since 1997. We 
found that oseltamivir resistant mutant strains do occur and their 
prevalence varies with host-species. This information is relevant 
to influenza pandemic preparedness, particularly with regard 
to choice of suitable pharmaceutical agents for stockpiling, and 
emphasizes the need for alternative therapies, including novel 
drugs and an effective vaccine. 
Materials and Methods
Sequence analysis. Sequences of H5N1 viruses sampled from 
1997 onwards were selected from our collection and public 
databases. Sequence data were aligned with and residue analysis 
performed using BioEdit (Version 7) [15]. Residues Glu 119, Arg 
292, His 274 and Arg 152 of the NA were selected to screen for 
predicted oseltamivir resistant mutants. 
Detection of H274Y mutant with specific PCR. The His274Tyr 
mutation on subtype 1 neuraminidase (N1) is caused 
by a C to T substitution at nucleotide position 763. 
Differential PCR was performed with two forward primers, 
primer C (5’ GAATTGGATGCTCCTAATTATC 3’) and primer 
T (5’ GAATTGGATGCTCCTAATTATT 3’) that differ by one 
nucleotide at the 3’ end, and a single reverse primer (5’ 
AGAGGACACCGGACCACAACTAC 3’).  The primer pairs were 
tested with His 274 and Tyr 274 reference templates to optimize 
conditions for primer specificity in mixtures of the two templates 
(95°C 10 min, 1 cycle; 95°C 1 min, 62°C 1 min, 72°C 1 min, 35 
cycles; 72°C 10 min, 1 cycle; Fig. 1).  RNA extraction and cDNA 
synthesis from virus samples were performed as described 
previously [2]. 
Inhibition of H5N1 virus infection in MDCK cell culture. Virus 
stocks were propagated in embryonated chicken eggs and 
TCID
50
 in MDCK cells was determined. Oseltamivir carboxylate 
(Roche) was tested at concentrations of 0.1 nM to 100 uM in a 
cell-based virus reduction assay, modified from that of Yen and 
co-workers [11]. Briefly, triplicate MDCK monolayer cultures 
in 96-well format were infected with 100 TCID
50
 virus doses (1 
hour, 37°C, 5% CO
2
), then the inoculum removed and cell layers 
washed with culture media (MEM, Gibco BRL). Two hundred 
microlitres of culture media containing the appropriate dilution 
of oseltamivir was added to wells, and cultures incubated for 3 
days (37°C, 5% CO
2
). The HA titers of individual well supernates 
were tested in duplicate. 
Quantification of wild type (C type) and mutant (T type) NA gene 
by quantitative PCR. Quantitative PCR (qPCR) reactions were 
performed with a Roche Lightcycler system (Roche) using 
a Lightcycler Faststart DNA Master SYBR Green I kit (Roche) 
according to the manufacturer’s instructions. For better 
discrimination between the wild type and mutant NA genes, 
Locked Nucleic Acid (LNA) primers (Proligo) were used. Wild 
type and mutant NA genes were cloned into the TOPO PCR 
2.1 vector (Invitrogen), sequenced and used as standards for 
quantification. Mutant and wild type NA gene copy number 
were calculated with Lightcycler software using the wild type 
and mutant plasmids as a standard. PCR specificity was checked 
by melting curve analysis and gel electrophoresis. 
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Results
Detection of an oseltamivir resistant H5N1 isolate. To date, four 
neuraminidase residue changes associated with resistance to 
oseltamivir have been characterized; Glu119Val, Arg292Lys, 
His274Tyr and Arg152Lys. These appear to be NA subtype 
specific; Arg292Lys and Glu119Val to N2 and His274Tyr to N1 
[16-18]. Published sequences of avian H5N1 virus isolates do 
not indicate the presence of resistance-associated mutations 
and the isolates tested are sensitive to oseltamivir inhibition 
both in vitro and in vivo [10,11]. However, the isolation of 
oseltamivir-resistant H5N1 viruses from humans in Vietnam 
indicates that oseltamivir resistance could be an emerging 
problem [13,14]. As oseltamivir is so important to pandemic 
preparedness, we wished to investigate if resistant mutant 
H5N1 viruses might be present in other species and areas in 
Asia, with a view to determining the potential of a naturally-
resistant pandemic strain arising in the future. Available 
sequences of H5N1 viruses isolated since 1997 were examined. 
One isolate, A/chicken/Hong Kong/3123.1/02, was found to 
bear the His274Tyr mutation which conveys resistance to 
neuraminidase inhibitor drugs in N1 subtype viruses [16-18]. 
Drug sensitivity tests revealed that this isolate possessed a high 
degree of resistance to oseltamivir inhibition, with an EC50 
of 124.9uM. In comparison, the A/chicken/Vietnam/37/04 
isolate, containing the wild type residue at position 274, has 
an EC50 of 0.4uM oseltamivir.
Figure 1. Sequencing traces of the neuraminidase gene showed a mixture of 
wild type (C) and H274 Y (T) mutant in an H5N1 ISOLATE (A). A C T Mutation at 
this position confers resistance to oseltamivir in H5N1 subtype viruses. Primers 
for wild type (C) and mutant (T) were designed with one nucleotide difference 
at the 3’ end of each primers were used with a common reverse primer derived 
from a non-variable region. Conditions allowing specific detection of wild 
type or mutant were potimized with templates containing only mutant or 
wild type and mixtures of these templates (B). Detection of wild type (primer 
W) AND his274tYR TYPE (PRIMER m) in H5N1 isolates and one orignial swab 
by PCR (C). 1: A/chicken/Vietnam/37/04, 2: A/chicken/Hong Kong/518.1/02, 3: 
A/chicken/485.2/02, 4: A/chicken/Vietnam/272/05, 5: A/chicken/Hong Kong/
WF75/02, 6: A/chicken/Hong Kong/WF75/02 (original swab). 
Presence of His 274Tyr mutant mixed with wild type virus in H5N1 
isolates. The human H5N1 virus isolated from patients treated 
with oseltamivir has been identified as consisting of mixed 
populations of His 274 wild type and Tyr 274 oseltamivir-
resistant virus [13,14]. As direct PCR product sequencing is the 
most regularly used method of determining influenza virus 
sequence, and sequence traces are rarely consulted, only the 
dominant sub-population at each nucleotide is represented 
in analyzed sequences, potentially obscuring the presence 
of low-frequency variant populations (Figure 1A). A protocol 
was developed and verified for rapid screening of H5N1 
isolates which may contain both mutant Tyr 274 and wild 
type His 274 NA1 (Figure 1B). Where available, original cloacal 
swabs corresponding to isolates identified as containing the 
His274Tyr mutant were compared with viral stocks to confirm 
that His274Tyr mutant virus was present in the original samples 
prior to viral propagation in embryonated eggs (Figure 1C). 
Overall, 54.3% of tested isolates contained detectable levels 
of His274Tyr variant virus, but the distribution was skewed, 
with variant detected most frequently in chicken isolates, less 
often in human and more rarely in duck and goose isolates 
(Table 1). His274Tyr mutant virus was not detected in a sample 
of nine H1N1 isolates tested using a similar procedure (data 
not shown). Species-specific analysis revealed that variant 
His274Tyr virus was not detected in chickens in the 1997-1999 
period (data not shown,). Following emergence of the mutant in 
2000, prevalence in chickens then rose rapidly, with just under 
10% of 2000-2001 viruses testing positive by PCR screening, 
and variant frequency plateauing at a high of 74% over the 
2002-2005 period. Geographical distribution of His274Tyr 
mutant virus was also analysed, but no distinct pattern could 
be discerned (data not shown).
table 1. Specific PCR screening for presence of His274Tyr mutation in H5N1 
viruses isolated from various hosts. 
Quantitative PCR was applied to quantify the relative 
abundance of His274Tyr mutant and the wild type in virus 
stocks. In essentially all isolates containing mixed species of 
wild type and mutant, the mutant represented less than 1% of 
the virus population, and in many cases less than 0.1% (data 
not shown).  
Discussion
Preparedness for a potential H5N1 influenza pandemic caused 
by currently-circulating H5N1 viruses has been recommended 
by the WHO. One well-publicized focus is the stockpiling of 
antiviral drugs, particularly inhibitors of viral neuraminidase. One 
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A
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Table 1  Specific PCR screening for presence of His274Tyr mutation in H5N1
viruses isolated from various hosts. 
Primer C Primer T
mu
tan
t
mi
xtu
re
mu
tan
t 
mi
xtu
re
Wi
ld 
typ
e
Wi
ld 
typ
e
B
Fig. 1B
Primer W (274H) Primer M (274Y)
2 3 64 51 2 3 64 51
C
Fig. 1C
156
Options for the Control of Influenza VI
such neuraminidase-inhibitor, oseltamivir, has been considered 
as one of the few options available for the containment of 
human-to-human transmission. This study demonstrates that 
oseltamivir resistant strains bearing the His274Tyr mutation are 
present in some H5N1 virus populations, albeit at low levels, in 
the absence of evidence of exposure to the drug. Oseltamivir 
is not known to have been introduced into the Hong Kong 
market prior to 2002, but we have detected His274Tyr mutants 
in virus populations isolated as early as 2000, which suggests 
that this mutant occurs naturally. Previous studies have shown 
that oseltamivir-resistant mutants have a growth and virulence 
disadvantage [19-22]. Given the continuous circulation of 
H5N1 viruses in poultry and wild birds in the southeast Asia 
region, there is a chance that His274Tyr mutants could gain the 
ability to increase in abundance if they obtain other adaptive 
changes. Even if variant viruses do not become dominant in 
mixed populations, they may still hamper clinical treatment 
with oseltamivir by increasing the overall resistance of the 
population. Isolation of one resistant mutant strain, A/chicken/
Hong Kong/3123.1/02, from an infected chicken suggests 
the possibility that such mutants may possess the potential 
to become the main population, at least in chickens. Major 
H5N1 outbreaks in poultry in 1997 and 2001-2002 in Hong 
Kong were controlled in a timely manner and this might have 
stopped further expansion of such mutants [23,24]. Antiviral 
drugs, if appropriately applied and tightly controlled, remain 
important components of pandemic preparedness. However, 
the presence of drug-resistant mutants in the pool of potential 
pandemic H5N1 strains provides additional “options” for the 
predicted pandemic strain, especially with regard to oseltamivir-
resistance. In anticipation of this possible scenario, further 
control options must be implemented, including stockpiling a 
wider range of drugs (zanamivir in particular), development of 
alternative pharmaceuticals, emphasis on vaccine development 
and, most importantly, increased surveillance for the presence 
of His274Tyr mutants mixed with wild type strains among new 
H5N1 isolates. 
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